Voluntary nationwide recall: Potassium (Glenmark – June)

Immediate (as of June 24, 2024): Billing team must coordinate with clinical staff and pharmacy to identify all patients who received Potassium Chloride Extended-Release Capsules (750 mg, 10 mEq) from Glenmark to determine batch numbers against the recall list. Before processing claims for potassium supplementation therapy, verify the product is NOT from the recalled batches. For patients on recalled batches: (1) ensure providers have instructed patients to consult their healthcare provider before discontinuing medication per FDA guidance, (2) coordinate with pharmacy on alternative potassium formulation, (3) update pharmacy billing records to reflect medication substitution, and (4) flag any existing claims for the recalled product for potential adjustment. Contact Inmar Rx Solutions at 1-877-883-9273 (TTY: 711, Mon-Fri 9am-5pm EST) or check FDA website for full batch number list. Document all actions taken in patient records and billing system to demonstrate due diligence.